Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ada Popolo has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polyphenolic Characterization, Antioxidant and Antihyperglycemic Activities of Crataegus spp. Fruit Extracts

    by Anna Cacciola, Shiva Pouramin Arabi, Valeria D’Angelo, Giuliana Donadio, Francesco Maria Raimondo, Valentina Santoro, Ada Popolo, Roberta Vitale, Emanuele Rosa, Maria Paola Germanò, et al.

    Crataegus L. (Rosaceae) comprises several species rich in nutrients and bioactive compounds with nutraceutical relevance. The present study aimed to investigate the polyphenolic profile, antioxidant activity, and in vitro antihyperglycemic-related activity of fruits from 11 Crataegus taxa collected in Western Sicily, a region characterized by a high diversity of this genus. Total polyphenol quantification indicated that, among the tested extracts, Crataegus laciniata exhibited the highest content (25.54 mg GAE/g). Using high-resolution Orbitrap Q-Exactive PLUS ESI-MS instrument (Thermo Fisher Scientific, Waltham, MA, USA), a comprehensive phytochemical characterization was performed. Hyperoside quantification revealed that Crataegus aff. insengae, Crataegus zichichii, and Crataegus drepanensis are rich in this bioactive compound (1.47, 1.22, 1.22 mg/g DW). Multivariate analysis, including principal component analysis (PCA), highlighted hyperoside and vitexin as the main contributors to sample differentiation. Additionally, Crataegus laciniata, Crataegus drepanensis, and Crataegus aff. insengae showed the highest antioxidant activity in chemical assays (DPPH, ABTS, and FRAP) and in Caco-2 and H9c2 cell models through the modulation of intracellular reactive oxygen species (ROS). Regarding antihyperglycemic-related activity, Crataegus laciniata, Crataegus azarolus var. azarolus, and Crataegus drepanensis extracts showed the best inhibitory activity against α-glucosidase and α-amylase. Overall, the study highlights the value of Crataegus fruits as sources of bioactive compounds for food and nutraceutical research and supports their further valorization.

  • Open Access

    Simvastatin Attenuates Doxorubicin-Induced Inflammation in Human Cardiomyocytes

    by Roberta Vitale, Rosaria Margherita Rispoli, Maria Carmela Di Marcantonio, Barbara Pala, Stefania Marzocco, Gabriella Mincione, Ada Popolo

    Background/Objectives: Clinical application of Doxorubicin (Doxo) is limited by cardiotoxicity, a process strongly associated with an interplay between oxidative stress and inflammatory signaling, particularly Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and Nucleotide oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome engagement. Identifying strategies capable of mitigating these interconnected pathways is of critical importance in cardio-oncology. Simvastatin (SIM) is a promising option since it modulates oxidative stress, inflammation, and cell death through its pleiotropic effects, so this study aimed to evaluate whether SIM attenuates Doxo-induced inflammatory responses. Methods: Human Cardiomyocyte (HCM) cells were pre-treated with SIM (10 µM) for 4 h and then co-exposed to SIM and Doxo (1 µM) for 20 h. Cytofluorimetric analysis was used to evaluate inducible nitric oxide synthase (iNOS), Connexin 43 (Cx43), and Cx43 phosphorylated at Serine 368 (pS368Cx43) levels. Real-time qPCR was performed to evaluate iNOS gene expression, while Nitric oxide (NO) release was evaluated by spectrophotometric analysis. Interleukin (IL)-1β, IL-18, IL-6, tumor necrosis factor alpha (TNF-α) production, and NLRP3 levels were evaluated by means of ELISA assay. Expression levels of inhibitor of nuclear factor kappa B alpha (IκB-α), Caspase-1, and Gasdermin D (GSDMD) were evaluated by Western Blot analysis. Nuclear translocation of NF-κB was evaluated by immunofluorescence assay. Results: In our experimental model, SIM significantly (p < 0.01) reduced Doxo-induced nitrite release, as well as iNOS gene expression (p < 0.05) and protein levels (p < 0.01). SIM also markedly attenuated Doxo-induced NF-κB signaling, pro-inflammatory cytokines production (TNF-α and IL-6, p < 0.01), and inflammosome-related responses (cleaved caspase-1, IL-1β, N-terminal domain of GSDMD), and NLRP3 expression p < 0.05). Additionally, SIM significantly attenuated the overexpression of Cx43 and its phosphorylated form (pS368Cx43), which are responsible for impairing intercellular communication and electrical coupling in cardiomyocytes and contribute to arrhythmias and conduction abnormalities characteristic of acute Doxo-induced cardiotoxicity. Conclusions: Overall, these findings demonstrate that SIM exerts a multifaceted cardioprotective effect against Doxo-induced injury, thereby targeting interconnected inflammatory and pro-arrhythmic pathways implicated in Doxo cardiotoxicity.

  • Open Access

    Plumericin Modulates the AhR–NFκB–Nrf2 Signaling Network to Counteract Indoxyl Sulfate-Induced Intestinal Epithelial Cells Impairment

    by Rosaria Margherita Rispoli, Stefan Schwaiger, Ada Popolo, Giuseppina Autore, Marco Gargaro, Hermann Stuppner, Stefania Marzocco

    Intestinal impairment plays a pivotal role in many chronic conditions, including chronic kidney disease (CKD), a progressive disorder affecting over 800 million people worldwide. CKD does not only affect the kidney, but it is recognized as a systemic condition characterized by chronic low-grade inflammation, that contributes to disease progression and associated complications. The intestine is one of the major sources of CKD-associated inflammation, also due to the production and accumulation of some uremic toxins, normally excreted by healthy kidneys, such as indoxyl sulfate (IS). IS is a pro-inflammatory and pro-oxidant protein-bound uremic toxin that increases intestinal epithelial permeability, promotes microbial translocation, and enhances inflammatory and oxidative responses. Although IS-induced intestinal damage has been documented, the underlying molecular mechanisms and effective therapeutic strategies to counteract its effects remain to be elucidated. Against this backdrop in the present study, we investigated the impact of plumericin, an iridoid spironolactone, on IS-induced intestinal impairment using IEC-6, an intestinal epithelial cells model. In IS-treated IEC-6, plumericin reduces apoptosis, inhibits inflammation and oxidative stress, and restores epithelial wound repair. In these conditions plumericin also promotes Nrf-2 and inhibits NF-kB and AhR activation induced by IS. Moreover, the same inhibitory effect of plumericin on inflammation and oxidative stress and in promoting wound repair is also observed in the presence of IS and pro-inflammatory stimuli, as occurs in CKD considering the associated systemic low-grade inflammation. These findings suggest that plumericin may represent a promising therapeutic candidate for intestinal impairment in CKD acting with an integrated mechanism.


  • Open Access

    Cardioprotective Effects of Simvastatin in Doxorubicin-Induced Acute Cardiomyocyte Injury

    by Roberta Vitale, Mariangela Mazzone, Maria Carmela Di Marcantonio, Stefania Marzocco, Gabriella Mincione, Ada Popolo

    Oxidative stress and mitochondrial dysfunction play a key role in the early stage of Doxorubicin (Doxo)-induced cardiotoxicity. Our study investigated the potential cardioprotective role of Simvastatin (Sim), widely known for its antioxidant properties, in an in vitro model of Doxo-induced acute cardiotoxicity. Human Cardiomyocytes (HCMs) were treated with Sim (10 µM, 4 h) and then co-exposed to Doxo (1 µM) and Sim for 20 h. Our data showed that Sim co-treatment significantly (p < 0.05) reduced both cytosolic and mitochondrial Doxo-induced reactive oxygen species overproduction. In Sim co-treated cells, significant reductions in nuclear factor erythroid 2-related factor 2 (Nrf2) gene expression (p < 0.01) and catalase (CAT), heme-oxygenase 1 (HO-1), and superoxide dismutase 2 (SOD2) levels (p < 0.05) compared to Doxo-treated cells were also demonstrated, suggesting a decreased need for compensatory antioxidant defense responses. Moreover, significant reductions in Doxo-induced mitochondrial calcium overload, mitochondrial membrane depolarization (p < 0.005), and apoptosis (p < 0.005) confirmed the protective effects of Sim co-treatment on cardiomyocytes. These data confirm that Sim could be a valuable therapeutic strategy for reducing Doxo-induced HCM damage, preventing the development of dilated cardiomyopathy and long-term heart damage, which are the main limitations of anthracycline use. Finally, real-time PCR analysis revealed that Sim co-treatment significantly reduced (p < 0.001) the Doxo-induced overexpression of MAP4K4, a mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) involved in oxidative stress-induced cell death, thus suggesting the involvement of other molecular mechanisms in Sim-mediated cardioprotection.


  • Top Cited Papers
    Open Access

    Targeting Inflammatory Imbalance in Chronic Kidney Disease: Focus on Anti-Inflammatory and Resolution Mediators

    by Rosaria Margherita Rispoli, Ada Popolo, Vincenzo De Fabrizio, Roberta D’emmanuele di Villa Bianca, Giuseppina Autore, Jesmond Dalli, Stefania Marzocco

    Chronic kidney disease (CKD) is a condition caused by the gradual decline of renal function that approximatively affects 10–12% of the world population, thus representing a public health priority. In CKD patients, chronic and systemic low-grade inflammation is observed, and it significantly contributes to disease development and progression, especially for patients with advanced disease. It also results in CKD-associated complications and increased mortality. The low-grade inflammation is due to different factors, such as the decline of glomerular filtration rate, increased immune system activation, reactive oxygen species release, and intestinal homeostasis. Therefore, the possibility to control chronic low-grade inflammation in CKD deserves great attention. In this review, we will examine the current possible pharmacological approaches to counteract the inflammatory state in CKD, focusing our attention both on the pro-inflammatory factors and the pro-resolving mediators involved in CKD inflammatory state.


  • Open Access

    A Targeted Mass Spectrometric Approach to Evaluate the Anti-Inflammatory Activity of the Major Metabolites of Foeniculum vulgare Mill. Waste in Human Bronchial Epithelium

    by Maria Assunta Crescenzi, Hector Gallart-Ayala, Cristiana Stellato, Ada Popolo, Julijana Ivanisevic, Sonia Piacente, Paola Montoro

    Fennel waste is rich in compounds that may have beneficial effects on human health. For this reason, the most abundant metabolites in fennel were isolated as the following: quercetin-3-O-glucoside, quinic acid, 1,5-dicaffeoylquinic acid, kaempferol-3-O-glucuronide, and quercetin-3-O-glucuronide. After inducing inflammation in human bronchial epithelial cells by stimulating them with IL-1β, the cells were treated with the specialized Foeniculum vulgare metabolites at different concentrations to assess their anti-inflammatory effect. Eicosanoids, fatty acids, and sphingolipids were extracted from the cell medium and quantified by UPLC-ESI-QTRAP-MS/MS analysis. The anti-inflammatory activity of the metabolites isolated from fennel waste was demonstrated. They were able to alleviate the inflammatory state in human bronchial epithelium by modulating the metabolic expression of both pro- and anti-inflammatory eicosanoids, fatty acids, and sphingolipids. These findings suggest the potential use of fennel waste in the production of dietary supplements to alleviate the symptoms of chronic inflammatory diseases like asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), where the continuous use of antiphlogistics may have significant side effects.


  • Open Access

    Simvastatin Enhances the Cytotoxic Effects of Doxorubicin in a Mammary Adenocarcinoma Cell Model by Involving Connexin 43

    by Roberta Vitale, Stefania Marzocco, Ada Popolo

    Gap Junctions channels formed by Connexins (Cx) provide intercellular communication enabling the coordination of cell growth, differentiation, and metabolism, and their reduction has been shown in many tumor types. Expression levels of Cx43, the most extensively studied Gap Junctions forming protein, are reduced or completely absent in breast cancer cells, while their overexpression correlates with increased cellular permeability to anticancer agents and, consequently, reduced resistance to drug treatments. So, drug associations targeting Cx43 are being considered to overcome chemoresistance. Previous studies demonstrated that Simvastatin (Sim) interferes with Cx43 expression and localization, and chemo‐sensitizing effects of Sim in several tumor cell lines treated with antineoplastic chemotherapeutics have been shown. This study aimed to evaluate whether Sim cotreatment enhances Doxorubicin‐induced cytotoxicity by affecting Cx43 expression and/or phosphorylation, so MCF‐7 cells were treated with Sim (10 µM) for 4 h and then coexposed to Sim and Doxorubicin (1 µM) for 20 h. In Sim cotreated cells, increased membrane levels of Cx43 have been shown; moreover, decreased levels of Cx43 phosphorylated on Ser368 and Ser262 residues, involved in channel closure and disruption of cell–cell communication, have been demonstrated in these cells. In Sim cotreated cells increased Doxorubicin uptake and enhanced Doxorubicin‐induced cytotoxic effects have been demonstrated together with reduced migratory capacity. Our data support the notion that Sim cotreatment could be a possible strategy to overcome chemoresistance, since the observed increase in Cx43 membrane levels, and the concomitant reduction of Cx43 phosphorylation, could be responsible for increased sensitization of cells to Doxorubicin treatment.


  • Top Cited Papers
    Open Access

    Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account

    by Roberta Vitale, Stefania Marzocco, Ada Popolo

    Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on the effects of long-term Doxo administration, but recent data show that cardiomyocyte damage is an early event induced by Doxo after a single administration that can be followed by progressive functional decline, leading to overt heart failure. The knowledge of molecular mechanisms involved in the early stage of Doxo-induced cardiotoxicity is of paramount importance to treating and/or preventing it. This review aims to illustrate several mechanisms thought to underlie Doxo-induced cardiotoxicity, such as oxidative and nitrosative stress, inflammation, and mitochondrial dysfunction. Moreover, here we report data from both in vitro and in vivo studies indicating new therapeutic strategies to prevent Doxo-induced cardiotoxicity.


  • Open Access

    Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account

    by Roberta Vitale, Stefania Marzocco, Ada Popolo

    Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on the effects of long-term Doxo administration, but recent data show that cardiomyocyte damage is an early event induced by Doxo after a single administration that can be followed by progressive functional decline, that lead to overt heart failure. The knowledge of molecular mechanisms involved in the early stage of Doxo induced cardiotoxicity is of paramount importance to treat and/or prevent it. This review aims to illustrate several mechanisms considered to underlie Doxo-induced cardiotoxicity, such as oxidative and nitrosative stress, inflammation, and mitochondrial dysfunction. Moreover, here we report data from both in vitro and in vivo studies indicating new therapeutic possibilities to prevent Doxo-induced cardiotoxicity.


  • Open Access

    Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity

    by Michela Pecoraro, Stefania Marzocco, Raffaella Belvedere, Antonello Petrella, Silvia Franceschelli, Ada Popolo

    This study aimed to evaluate if Simvastatin can reduce, and/or prevent, Doxorubicin (Doxo)-induced cardiotoxicity. H9c2 cells were treated with Simvastatin (10 µM) for 4 h and then Doxo (1 µM) was added, and the effects on oxidative stress, calcium homeostasis, and apoptosis were evaluated after 20 h. Furthermore, we evaluated the effects of Simvastatin and Doxo co-treatment on Connexin 43 (Cx43) expression and localization, since this transmembrane protein forming gap junctions is widely involved in cardioprotection. Cytofluorimetric analysis showed that Simvastatin co-treatment significantly reduced Doxo-induced cytosolic and mitochondrial ROS overproduction, apoptosis, and cytochrome c release. Spectrofluorimetric analysis performed by means of Fura2 showed that Simvastatin co-treatment reduced calcium levels stored in mitochondria and restored cytosolic calcium storage. Western blot, immunofluorescence, and cytofluorimetric analyses showed that Simvastatin co-treatment significantly reduced Doxo-induced mitochondrial Cx43 over-expression and significantly increased the membrane levels of Cx43 phosphorylated on Ser368. We hypothesized that the reduced expression of mitochondrial Cx43 could justify the reduced levels of calcium stored in mitochondria and the consequent induction of apoptosis observed in Simvastatin co-treated cells. Moreover, the increased membrane levels of Cx43 phosphorylated on Ser368, which is responsible for the closed conformational state of the gap junction, let us to hypothesize that Simvastatin leads to cell-to-cell communication interruption to block the propagation of Doxo-induced harmful stimuli. Based on these results, we can conclude that Simvastatin could be a good adjuvant in Doxo anticancer therapy. Indeed, we confirmed its antioxidant and antiapoptotic activity, and, above all, we highlighted that Simvastatin interferes with expression and cellular localization of Cx43 that is widely involved in cardioprotection.